Sacchetti, E
Magri, C
Minelli, A
Valsecchi, P
Traversa, M
Calza, S
Vita, A
Gennarelli, M
Article History
Received: 29 November 2014
Revised: 26 August 2015
Accepted: 16 October 2015
First Online: 9 February 2016
Competing interests
: In the past 3 years, ES has received funding for research, advisory board membership and sponsored lectures from the following private companies: Angelini, Chiesi, Content Rd Net srl, EDRA LSWR, Eli Lilly, Health and Publishing Services srl, Janssen-Cilag, Lundbeck, McCann, Otsuka, Pfizer, Roche, Servier, Stroder, Sunovion, Takeda and Valeas. He is not a shareholder in any of these corporations. In the past 3 years, AV has received funding for research, advisory board membership and sponsored lectures from Astra Zeneca Pharmaceuticals, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer, Otsuka, Sanofi and Stroder. He is not a shareholder in any of these corporations. PV has received funding for research and sponsored lectures from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Innova Pharma, Janssen-Cilag, Lundbeck, Otsuka, Pfizer and Wyeth Lederle. He is not a shareholder in any of these corporations. The authors declare no conflicts of interest.